# Foxo Technologies Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Foxo Technologies Inc.). ## Overview FOXO Technologies Inc. is a U.S.-based healthcare and life-sciences company built around two operating areas: healthcare services and Labs/Life research and testing activities. Its business combines acquired healthcare operations with epigenetic biomarker research, bioinformatics services, and royalty/commission-based revenue streams tied to longevity and life-insurance-related activities. ## Products & services • Healthcare services: hospital, ancillary, and substance use disorder treatment • Epigenetic testing services for research organizations • Bioinformatics Services using FOXO’s cloud-based pipeline • Royalties from epigenetic biomarker research and related IP • Life insurance policy sales/servicing commissions • AI/ML epigenetic app development under the KR8 license - **Healthcare Services** (95%) — Hospital, ancillary, and substance use disorder treatment services delivered through acquired operations. - **Labs and Life Services** (5%) — Epigenetic testing, bioinformatics services, royalties, and life-insurance-related commissions. - Healthcare services including inpatient, outpatient, and ancillary care - Substance use disorder treatment services - Epigenetic testing and biomarker research services - Bioinformatics data processing, quality checking, and analysis - Royalties and commissions from epigenetic and life-insurance activities - AI machine-learning epigenetic consumer app development ## Customers The company serves healthcare patients and payers through its acquired healthcare operations, with revenue driven by hospital and ancillary services and substance use disorder treatment. Its Labs and Life activities sell to research organizations and other counterparties that need epigenetic testing, data processing, or access to FOXO-related biomarker IP. The KR8 app initiative also targets consumer health and wellness use cases, although it remains a licensing and development effort rather than a mature revenue engine. - **Healthcare patients and payers** (primary) — Patients receive hospital and treatment services, while insurers and government programs reimburse a large share of the revenue. - **Research organizations** (secondary) — Buy epigenetic testing and bioinformatics services for data analysis and biomarker-related research. - **Royalty and commission counterparties** (secondary) — Generate small revenue streams from biomarker-related royalties and life insurance policy commissions. - **Consumer wellness users** (emerging) — Potential users of the AI epigenetic app being developed under the KR8 agreement. - Patients using hospital, outpatient, and ancillary healthcare services - Third-party payers and managed care organizations reimbursing care - Substance use disorder patients and treatment providers - Research organizations buying epigenetic testing and analysis - Counterparties paying royalties or commissions tied to FOXO IP - Potential consumer wellness users of the epigenetic app platform ## Geography FOXO’s disclosed operating territory for the KR8 license is limited to the U.S., Canada, and Mexico, indicating a North American focus for that product initiative. The company is U.S.-based and its healthcare revenue is generated domestically, with reimbursement and collection risk tied to U.S. payer dynamics. No country-level revenue split was disclosed in the provided excerpts. - U.S. is the core operating market for healthcare revenue - KR8 license territory covers the U.S., Canada, and Mexico - North American scope matters for app commercialization rights - Revenue depends on U.S. payer and patient collection dynamics - No country-level revenue disclosure was provided in the excerpts ## Strategy Management is focused on keeping the business funded while scaling acquired healthcare operations and extracting cash flow from Myrtle and RCHI/SCCH. The company is also pursuing additional financing and strategic acquisitions that can contribute positive cash flow, while developing bioinformatics and epigenetic product offerings that could broaden the revenue base. Liquidity preservation and selective capital deployment are central because the company states it does not have sufficient capital to fund corporate overhead for at least 12 months without additional financing. - **Stabilize liquidity and fund operations** (short-term) — The company says current cash is insufficient to fund overhead without new financing. - **Integrate and monetize acquired healthcare assets** (short-term) — Myrtle and RCHI/SCCH are expected to produce a small cash flow surplus through 2025. - **Build Labs bioinformatics into a primary offering** (medium-term) — Bioinformatics services can broaden the company beyond healthcare reimbursement economics. - **Commercialize epigenetic consumer and research applications** (medium-term) — The KR8 license and epigenetic testing services could create higher-value recurring revenue. - Use acquired healthcare businesses to generate operating cash - Expand Labs bioinformatics as a more primary offering - Pursue additional acquisitions that can add positive cash flow - Raise equity or debt to fund operations and growth - Conserve cash through non-cash settlements and equity issuances - Develop the KR8 epigenetic app for consumer engagement ## Risks FOXO faces substantial going-concern and financing risk because management states it cannot fund operations for at least 12 months without additional capital. Its healthcare revenue is highly exposed to payer reimbursement, contractual allowances, and collection performance, while the Labs/Life business remains small and less proven. The company also carries execution risk around acquisitions, integration, and commercialization of new epigenetic products, all while operating in a regulated healthcare environment. - **Insufficient liquidity / going concern** [critical] — Management says current cash is not enough to fund corporate overhead for 12 months. - **Payer reimbursement and collection risk** [high] — Healthcare revenue is recorded net of contractual allowances and implicit price concessions. - **Acquisition integration risk** [high] — Recent acquisitions must be integrated and turned into positive cash flow. - **Dilution and capital structure risk** [high] — Funding may require equity issuance, convertible debt, or non-cash settlements. - Going-concern risk if new financing is not secured - High dependence on payer collections and reimbursement rates - Revenue volatility from contractual allowances and implicit concessions - Integration risk from recent healthcare acquisitions - Small Labs/Life revenue base may not offset healthcare volatility - Dilution risk from equity-funded financing and non-cash settlements ## Accounting Revenue recognition is a key accounting issue because healthcare revenue is reported net of estimated contractual allowances and implicit price concessions, which can materially change reported net revenue and receivables. The company also relies on estimates for collectability, doubtful accounts, and fair presentation of healthcare receivables, making earnings sensitive to payer mix and collection assumptions. Because the business is small and acquisition-driven, impairment, valuation, and estimate changes can have outsized effects on reported results. - **Revenue recognition under Topic 606** — Reported revenue and accounts receivable - **Allowance and collectability estimates** — Revenue, receivables, and bad debt-related adjustments - **Going-concern assessment** — Balance sheet and disclosure risk - **Acquisition-related valuation judgments** — Assets, liabilities, and future impairment risk - Healthcare revenue is net of contractual allowances and price concessions - Receivables are recorded at estimated realizable value, not gross billings - Collection estimates can materially change reported revenue - Acquisition accounting and valuation judgments may affect results - Going-concern disclosures highlight uncertainty in financial statement preparation --- *Last updated: 2026-04-28T20:07:22.876749+00:00*